Result of Placing
Creo Medical Group plc has successfully raised gross proceeds of £5.5 million through a placing of 36,666,664 new ordinary shares at an issue price of 15 pence per share, representing a premium to the previous closing price. This fundraising strengthens the company's balance sheet and positions it to capitalize on commercial and strategic momentum, with directors participating by subscribing for £2.15 million worth of shares. Admission of the new shares to AIM is expected on May 28, 2026, at which point the total issued share capital will be 449,139,983 ordinary shares.
Select text to share a quote on X · sign in to keep highlights & notes in your CREO notes
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES AND DOES NOT CONSTITUTE AN OFFER IN RESPECT OF ANY SECURITIES OF CREO MEDICAL GROUP PLC AND NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, FORMS OR IS INTENDED TO FORM THE BASIS FOR ANY INVESTMENT DECISION IN RESPECT OF CREO MEDICAL GROUP PLC OR OTHER EVALUATION OF ANY SECURITIES OF CREO MEDICAL GROUP PLC OR ANY OTHER ENTITY AND SHOULD NOT BE CONSIDERED AS A RECOMMENDATION THAT ANY INVESTOR SHOULD SUBSCRIBE FOR OR PURCHASE ANY SUCH SECURITIES.
Creo Medical Group plc
Result of Placing
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients (the "Company" or "Creo" and, together with its subsidiary undertakings, the "Group"), announces that, further to the announcement made earlier today regarding the Placing (the "Launch Announcement"), it has raised gross proceeds of £5.5 million by way of a placing of 36,666,664 new ordinary shares of 0.1 pence each (the "Ordinary Shares") in the capital of the Company (the "Placing Shares") at a price of 15 pence per Placing Share (the "Issue Price").
The Issue Price represents a premium of approximately 31.9 per cent. to the closing middle market price of 11.4 pence per Existing Ordinary Share on 21 May 2026, being the latest practicable date prior to the publication of the Launch Announcement.
Allocations in the Placing will be confirmed to Placees as soon as practicable today.
Shore Capital Stockbrokers Limited ("Shore Capital" or the "Bookrunner") is acting as sole bookrunner in connection with the Placing.
Craig Gulliford, Chief Executive Officer of Creo Medical, said:
"We are very pleased to have received this strong support from investors for our business and strategy.
"The Placing, alongside the other strategic funding initiatives we announced this morning, strengthens the Group's balance sheet and positions Creo to capitalise on the strong recent commercial and strategic momentum across our business.
"We are seeing strong growth for our products and believe there is a substantial opportunity as we expand the commercialisation of our product portfolio and integrate our advanced energy technology into a wide range of surgical platforms and robotics."
Directors' participation in the Placing and Related Party Transactions
The following directors of the Company (the "Directors") have subscribed for a total of 14,333,332 Placing Shares (the "Participating Directors"), representing an aggregate amount of £2.15 million, as set out below:
| Director | Number of Placing Shares subscribed for | Shareholding following Admission | Percentage shareholding of enlarged issued share capital on Admission (%) |
|---|---|---|---|
| K evin Crofton | 13,333,333 | 18,780,749 | 4.18 |
| Craig Gulliford 1 | 333,333 | 2,043,635 | 0.46 |
| Richard Rees | 666,666 | 3,398,329 | 0.76 |
1 via a self-invested personal pension
Further detail on the Directors' participations, required in accordance with UK MAR, is set out at the end of this Announcement.
The participation of each of the Participating Directors in the Placing in aggregate constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The independent directors for the purposes of Rule 13 of the AIM Rules (being Ivonne Cantu and Brent Boucher), having consulted with Deutsche Numis, the Company's nominated adviser, consider the terms of the related party transaction to be fair and reasonable insofar as shareholders of the Company are concerned.
Admission, settlement and dealings
Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on the AIM market of the London Stock Exchange ("Admission").
Admission is expected to take place at 8.00 a.m. on 28 May 2026 and dealings in the Placing Shares are expected to commence at 8.00 a.m. on 28 May 2026 or, in each case, such later time and/or date as the Bookrunner and the Company agree (being in any event no later than 8.00 a.m. on 9 June 2026).
Total voting rights
Following Admission, the total issued capital of the Company will consist of 449,139,983 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 449,139,983 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
The information below (set out in accordance with the requirements of UK MAR) provides further detail. PDMR Notification Forms:
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | 1) Kevin Crofton 2) Craig Gulliford 3) Richard Rees |
| 2 | Reason for the notification | |
| a) | Position/status | 1) Chair 2) CEO 3) CFO |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Creo Medical Group plc |
| b) | LEI | 213800H188ZDCWWXFA21 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.1 pence each |
| Identification code | GB00BZ1BLL44 | |
| b) | Nature of the transaction | 1. Purchase of Placing Shares 2. Purchase of Placing Shares into a SIPP 3. Purchase of Placing Shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1. 15p 13,333,333 2. 15p 333,333 3. 15p 666,666 |
| d) | Aggregated information Aggregate volume Price | N/A - single transactions |
| e) | Date of the transaction | 22 May 2026 |
| f) | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.